



## **INTERNET CME REQUIREMENTS**

### **ACCME Policy for CME Delivered via the Internet (effective October 1, 2002)**

1. CME activities delivered via the Internet are expected to be in compliance with ACCME Essential Areas, Elements, and Policies.
2. There shall be no CME activities of an ACCME accredited provider on a pharmaceutical or device manufacturers' product website.
3. With clear notification that the learner is leaving the educational website, links from the website of an ACCME accredited provider to pharmaceutical and device manufacturers' product websites are permitted before or after the educational content of a CME activity, but shall not be embedded in the educational content of a CME activity.
4. Advertising of any type is prohibited within the educational content of CME activities on the Internet including, but not limited to, banner ads, subliminal ads, and pop-up window ads.
5. The accredited provider must indicate, at the start of each Internet CME activity, the hardware and software required for the learner to participate.
6. The accredited provider must have a mechanism in place for the learner to be able to contact the provider if there are questions about the Internet CME activity.
7. The accredited provider must have, adhere to, and inform the learner about its policy on privacy and confidentiality that relates to the CME activities it provides on the Internet.
8. The accredited provider must be able to document that it owns the copyright for, or has received permissions for use of, or is otherwise permitted to use copyrighted materials within a CME activity on the Internet.

### **Opening Screen**

- CIN Strategies: Anticipate, Manage, Prevent
- Release date: May 2007  
Expiration date: May 2008
- Estimated time to complete activity: 1 hour and 15 minutes
- Notice as to the type of hardware and software needed to participate in the activity
- Mechanism for the learner to contact PIM
- Hyperlink to PIM's website (pimed.com)
- (PIM Logo) Sponsored by Postgraduate Institute for Medicine
- (Logo) This activity is supported by an educational grant from Tyco Healthcare/Mallinckrodt Imaging

## **Front Matter of the Offering**

### *Target Audience*

*This activity has been designed to meet the educational needs of radiologists and interventional cardiologists involved in the management of patients with contrast-induced nephropathy.*

### *Statement of Need/Program Overview*

During the past 30 years, computed tomography (CT) scanning has become a well-established procedure in helping to confirm and establish a medical diagnosis via radiological studies. In the United States, nearly 50 million CT procedures are performed annually. To improve the quality and diagnostic value of these procedures intravenous contrast media may be utilized – in fact, contrast media was utilized in nearly 25 million of the aforementioned CT procedures. Yet, the benefits of using intravenous contrast are not without risks, specifically contrast-induced nephropathy (CIN.) Contrast media themselves have the potential to injure the kidney, thereby leading to acute hemodynamic and/or nephrotoxic acute renal failure. CIN is reported to be the 3<sup>rd</sup> most common cause of acute renal failure among hospitalized patients. CIN can also significantly increase the risk of morbidity and mortality. Thus, it is imperative that physicians and clinicians who utilize contrast media in their practices be cognizant not only of the benefits of these agents, but also of the risks associated with their use – particularly CIN. The articles that comprise this scientific supplement will provide these clinicians with the information and strategies necessary to address the clinical issues and challenges surrounding intravenous contrast and CIN.

### *Educational Objectives*

*After completing this activity, the participant should be better able to:*

- Identify patients at possible risk of contrast-induced nephropathy
- Identify strategies for reducing the risk of contrast-induced nephropathy
- Explain how the choice of contrast can impact the risk of contrast-induced nephropathy
- Identify new medical developments in prophylaxis against contrast-induced nephropathy

### *Faculty*

Richard J. Solomon, MD  
Professor of Medicine  
University of Vermont College of Medicine  
Burlington, VA

Michael R. Rudnick, MD  
Associate Professor of Medicine  
Chief, Renal Electrolyte and Hypertension Division  
University of Pennsylvania School of Medicine  
Philadelphia, PA

Sanjay Saini, MD  
Associate Professor  
Harvard Medical School

Department of Radiology  
Massachusetts General Hospital  
Boston, MA

Garry Choy, MD  
Clinical Fellow  
Harvard Medical School  
Department of Radiology  
Massachusetts General Hospital  
Boston, MA

*Accreditation Statement*

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and SynerMed Communications. PIM is accredited by the ACCME to provide continuing medical education for physicians.

*Credit Designation*

Postgraduate Institute for Medicine designates this educational activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)<sup>™</sup>. Physicians should only claim credit commensurate with the extent of their participation in the activity.

*Disclosure of Conflicts of Interest*

Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The *faculty* reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

**Richard Solomon, MD**

Consulting Fees: Bracco Diagnostics, Tyco-Mallinckrodt  
Speaker's Bureau and Contracted Research: Bracco Diagnostics

**Garry Choy, MD**

He or his spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interests related to the content of this CME activity of any amount during the past 12 months.

**Sanjay Saini, MD**

He or his spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interests related to the content of this CME activity of any amount during the past 12 months.

**Michael Rudnick, MD**

Consulting Fees: General Electric Health Care, Salix Pharmaceuticals

The following PIM clinical content reviewers, Jan Hixon, RN; Linda Graham, RN; and Trace Hutchison, PharmD and SynerMed Communications Robert Schneider, Cheryl Proval, and Kris Keyes state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interests related to the content of this CME activity of any amount during the past 12 months.

#### *Method of Participation*

There are no fees for participating and receiving CME credit for this activity. During the period May 2007 through May 31, 2008, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the posttest by recording the best answer to each question in the answer key on the evaluation form; 4) complete the evaluation form; and 5) mail or fax the evaluation form with answer key to Postgraduate Institute for Medicine.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better. Your statement of credit will be mailed to you within 3 weeks.

#### *Media*

Newsletter

#### *Disclosure of Unlabeled Use*

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Postgraduate Institute for Medicine (PIM), SynerMed Communications and Tyco/Healthcare/Mallinckrodt do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, SynerMed Communications and Tyco/Healthcare/Mallinckrodt. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

#### *Disclaimer*

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.